These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7908879)

  • 21. H2 histamine receptor blockade in the treatment of Alzheimer disease: a randomized, double-blind, placebo-controlled trial of nizatidine.
    Carlson MC; Tschanz JT; Norton MC; Welsh-Bohmer K; Martin BK; Breitner JC
    Alzheimer Dis Assoc Disord; 2002; 16(1):24-30. PubMed ID: 11882746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacology update. Anti-peptic ulcer agents--Part I. A histamine 2 receptor antagonist.
    Romankiewicz JA
    J Pract Nurs; 1981 Jan; 31(1):15-6. PubMed ID: 6108367
    [No Abstract]   [Full Text] [Related]  

  • 23. Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man.
    Said SA; Foda AM
    Arzneimittelforschung; 1989 Jul; 39(7):790-2. PubMed ID: 2783182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
    Dammann HG; Gottlieb WR; Walter TA; Dreyer M; Müller P; Simon B; Keohane P
    Hepatogastroenterology; 1986 Oct; 33(5):217-20. PubMed ID: 2879782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacology of H2-receptor antagonists: an overview.
    Schunack W
    J Int Med Res; 1989; 17 Suppl 1():9A-16A. PubMed ID: 2566544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.
    Price AH; Brogden RN
    Drugs; 1988 Nov; 36(5):521-39. PubMed ID: 2905640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nizatidine versus ranitidine in the treatment of peptic ulcer disease: report on the Dutch investigation as part of a European multicentre trial.
    Kuipers EJ; Hazenberg HJ; Quik RF; Hazenberg BP; de Zwart PA
    Neth J Med; 1990 Aug; 37(1-2):58-62. PubMed ID: 1977089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.
    Brogden RN; Carmine AA; Heel RC; Speight TM; Avery GS
    Drugs; 1982 Oct; 24(4):267-303. PubMed ID: 6128216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam.
    Richardson CJ; Blocka KL; Ross SG; Verbeeck RK
    Eur J Clin Pharmacol; 1987; 32(1):89-91. PubMed ID: 3582473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical use of histamine-2 receptor antagonists.
    Michocki RJ; Richardson JP
    Md Med J; 1992 May; 41(5):397-400. PubMed ID: 1625532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the efficacy, safety, and pharmacokinetic profiles of extended-release ketoprofen and piroxicam in patients with rheumatoid arthritis.
    Caldwell JR
    Clin Ther; 1994; 16(2):222-35. PubMed ID: 8062318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A lack of pharmacokinetic interaction between ranitidine and piroxicam.
    Dixon JS; Lacey LF; Pickup ME; Langley SJ; Page MC
    Eur J Clin Pharmacol; 1990; 39(6):583-6. PubMed ID: 1982764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cimetidine 6 years later: a review.
    Gledhill T
    Can J Surg; 1983 Jul; 26(4):312-5. PubMed ID: 6134575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral bioavailability of CHF1194, an inclusion complex of piroxicam and beta-cyclodextrin, in healthy subjects under single dose and steady-state conditions.
    Deroubaix X; Stockis A; Allemon AM; Lebacq E; Acerbi D; Ventura P
    Eur J Clin Pharmacol; 1995; 47(6):531-6. PubMed ID: 7768257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis.
    Tracy TS; Worster T; Bradley JD; Greene PK; Brater DC
    Br J Clin Pharmacol; 1994 May; 37(5):453-6. PubMed ID: 8054251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endocrine effects of a new histamine H2-receptor antagonist, nizatidine (LY139037), in the male rat.
    Neubauer BL; Goode RL; Best KL; Hirsch KS; Lin TM; Pioch RP; Probst KS; Tinsley FC; Shaar CJ
    Toxicol Appl Pharmacol; 1990 Feb; 102(2):219-32. PubMed ID: 1967857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of peptic ulcer in the Zollinger-Ellison syndrome with histamine H2-receptor antagonists (author's transl)].
    Hausamen TU; Fritsch WP; Scholten T; Jungblut R; Strohmeyer G
    Dtsch Med Wochenschr; 1977 Nov; 102(47):1709-12. PubMed ID: 21785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Recent developments in drugs antagonistic to factors causing peptic ulcer--clinical effects and problems; histamine H2 receptor blockaders].
    Tani N; Miwa T
    Nihon Rinsho; 1988 Jan; 46(1):12-7. PubMed ID: 2897482
    [No Abstract]   [Full Text] [Related]  

  • 39. [Cimetidine and recent H2-receptor blocking agents in the therapy of gastrointestinal diseases].
    Gugler R; Musch E
    Med Welt; 1982 Aug; 33(31-32):1083-86. PubMed ID: 6127590
    [No Abstract]   [Full Text] [Related]  

  • 40. Aplastic anemia associated with initiation of nizatidine therapy in a hemodialysis patient.
    Nakano T; Kuroiwa T; Tsumita Y; Kaneko Y; Hiromura K; Ueki K; Nojima Y
    Clin Exp Nephrol; 2004 Jun; 8(2):160-2. PubMed ID: 15235935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.